British Journal of Pharmacy and Pharmaceutical Sciences
ISSN: 3049-8732
DOI: 10.32996/bjpps
Journal Homepage: www.al-kindipublisher.com/index.php/bjpps

BJPPS
AL-KINDI CENTER FOR RESEARCH AND DEVELOPMENT

| RESEARCH ARTICLE

AI-Powered Predictive Models for Rapid Detection of Novel Drug-Drug Interactions in Polypharmacy Patients

Abena Ntim Asamoah
The Trust Hospital, Ghana
Corresponding Author: Abena Ntim Asamoah, **E-mail**: abnasamoah@gmail.com

| ABSTRACT
Polypharmacy, which is the usage of multiple drugs concomitantly, is highly dangerous due to adverse drug-drug interactions (DDIs) especially in vulnerable groups of patients. The conventional pharmacovigilance techniques are not always capable of identifying new or uncommon DDIs in the shortest time possible, which makes novel approaches to drug safety a necessity. Artificial intelligence (AI) has become an influential tool that can be used to combine various types of data, such as electronic health records, molecular databases, and post-marketing surveillance reports, to forecast and detect the obscured types of interactions with utmost accuracy. Artificial intelligence (AI) predictive models provide disruptive potential in clinical pharmacy, providing opportunities to apply real-time risk stratification, prescribing practice optimization, and prevent adverse events. The models are also helpful in drug discovery, development and repurposing development since it hastens the initial recognition of safety cues. Although there are various obstacles to consider concerning data quality, transparency, and ethical issues, AI-based systems are a way to move towards safer and more individualized medication management. AI can transform the future of clinical practice and pharmacovigilance by increasing the detection and management of DDIs in patients with polypharmacy.

| KEYWORDS

Polypharmacy, Artificial Intelligence, Predictive Models, Drug-Drug Interactions, Pharmacovigilance, Personalized Medicine

| ARTICLE INFORMATION

ACCEPTED: 01 April 2024 **PUBLISHED:** 28 April 2024 **DOI:** 10.32996/bjpps.2024.1.1.8

1. Introduction

Polypharmacy, which refers to the concomitant use of several medications by a patient, is one of the most frequent modern healthcare practices that have increased in frequency because of the increase in the number of chronic diseases, the number of multimorbidities, and aging (Hartshorne, 2023). Although polypharmacy may be clinically required, it is widely recognized to be linked with increased risks of drug-drug interactions (DDI), adverse drug event, decreased adherence, and higher healthcare expenses (Shirazibeheshti et al., 2023). Identification of DDIs, especially new or unexpected interactions, is still a major problem to clinicians because conventional pharmacovigilance systems lack the capability to detect intricate interaction patterns (Soldatos et al., 2022).

Artificial intelligence (AI) has emerged as a transformative tool in healthcare, capable of addressing these limitations through predictive analytics, machine learning (ML), and advanced data integration (Roski et al., 2019). In clinical pharmacy, AI has shown potential in enhancing drug safety, improving adherence, and supporting patient-centered care through decision-support systems that reduce human error and optimize prescribing practices (Ogbuagu et al., 2023). Moreover, AI-powered models can leverage large-scale electronic health records, molecular data, and post-marketing surveillance reports to identify hidden patterns of drug interactions that might otherwise go unnoticed (Banerjee et al., 2022; Soldatos et al., 2022).

According to the latest developments, AI is utilized in risk stratification, especially in identifying patients who are more prone to the polypharmacy-associated risks of adverse events related to anticholinergic and sedative drugs (Shirazibeheshti et al., 2023). Predictive algorithms are able to identify vulnerable patients early enough and clinicians can provide interventions before the damage is done. Moreover, pharmacovigilance is becoming more AI-controlled with drugs discovery and development pipelines that can faster identify potential interactions in a preclinical, clinical and post-marketing setting (Mahmood, 2019; Niazi, 2023).

In addition to pharmacovigilance, AI is involved in drug repurposing where it finds alternative applications of existing drugs at the same time determining potential cross-drug responses (Selvaraj et al., 2021). Likewise, predictive models have been used to streamline clinical pathways, offering individual treatment advice with the least adverse interactions (Ganti, 2023). These applications do not only expand the role of AI as a diagnostic device but also as a tool that actively influences therapeutic decision-making in a real-world clinical practice (Ganesh et al., 2022; Mittal et al., 2023).

However, irrespective of these developments, a number of challenges exist. Much of the limiting factors to large-scale adoption in clinical practice are data heterogeneity, interpretability of AI models, and ethical issues of transparency and accountability (Roski et al., 2019). Furthermore, the introduction of AI to healthcare systems will need not just the strong technical solutions but also the confidence of clinicians, regulatory authority, and acceptance of patients (Prakash et al., 2023). However, the accumulating evidence base indicates that predictive models powered by AI have high potential in the further development of the high-speed identification of new DDIs, which ultimately will lead to safer prescribing behaviors and better patient outcomes during polypharmacy care (Hartshorne, 2023; Ogbuagu et al., 2023).

2. Role of AI in Drug Safety and Polypharmacy Management

Polypharmacy, defined as the concurrent use of multiple medications, is increasingly prevalent among aging populations and individuals with complex chronic conditions. While often necessary, polypharmacy heightens the risk of adverse drug reactions (ADRs), drug-drug interactions (DDIs), and medication non-adherence, thereby posing significant safety concerns (Hartshorne, 2023; Shirazibeheshti et al., 2023). Traditional pharmacovigilance approaches often struggle with timely detection of novel or rare interactions, highlighting the need for AI-driven solutions to enhance safety monitoring and rational prescribing.

2.1 AI for Drug Safety Monitoring

Artificial intelligence has demonstrated utility in integrating large-scale molecular, clinical, and post-marketing datasets to enhance early signal detection of adverse events (Soldatos et al., 2022). Machine learning algorithms can identify subtle, previously overlooked patterns that may indicate emerging DDIs, thereby improving pharmacovigilance processes (Ganesh et al., 2022). Furthermore, natural language processing (NLP) enables extraction of critical safety insights from electronic health records (EHRs) and unstructured clinical notes (Banerjee et al., 2022).

2.2 AI in Polypharmacy Risk Stratification

AI-based predictive modeling facilitates risk stratification by identifying patients most vulnerable to medication-related harm, such as those exposed to anticholinergic or sedative polypharmacy (Shirazibeheshti et al., 2023). Clinical decision support systems powered by AI can provide real-time alerts on potential interactions, dosage errors, or duplicate therapies, thereby reducing prescribing risks (Ogbuagu et al., 2023). These systems also support personalized medication optimization by tailoring regimens to individual patient needs and comorbidity profiles (Ganti, 2023).

2.3 Enhancing Clinical Pharmacy Practice

AI contributes to patient-centered care by improving medication adherence monitoring, predicting potential non-compliance, and guiding interventions that enhance safety and outcomes (Ogbuagu et al., 2023). In clinical settings, AI-enabled tools augment pharmacist decision-making by analyzing patient histories, laboratory data, and treatment pathways to minimize avoidable ADRs.

2.4 Table 1: Summary of AI Applications in Polypharmacy Management

AI Application	Function in Drug Safety & Polypharmacy	Key Benefits	References
Pharmacovigilance & ADR detection	Mining EHRs, clinical notes, and adverse event reports	Early detection of novel DDIs, improved drug safety monitoring	Soldatos et al., 2022; Banerjee et al., 2022
Risk stratification	Identifying high-risk polypharmacy patients (e.g., anticholinergic use)	Prevents severe ADRs, supports proactive care	Shirazibeheshti et al., 2023; Hartshorne, 2023
Clinical decision support	Real-time prescribing alerts and drug interaction checks	Reduces prescribing errors, improves rational prescribing	Ogbuagu et al., 2023; Ganesh et al., 2022
Personalized treatment planning	Optimizing regimens via AI-driven clinical pathway models	Enhances patient outcomes, supports precision medicine	Ganti, 2023; Selvaraj et al., 2021
Medication adherence monitoring	Predicting non-compliance and guiding interventions	Improves adherence, reduces hospitalization risks	Ogbuagu et al., 2023; Gellert et al., 2023

2.5 Challenges and Considerations

Despite these advances, the adoption of AI in polypharmacy management faces barriers including data fragmentation, algorithm interpretability, and ethical considerations regarding transparency and accountability (Roski et al., 2019; Niazi, 2023). Addressing these challenges is essential for successful integration of AI-driven drug safety models into mainstream healthcare practice.

3. AI-Powered Predictive Models for Drug-Drug Interactions

The complexity of polypharmacy makes it increasingly difficult for clinicians to anticipate drug-drug interactions (DDIs) through traditional pharmacovigilance or clinical experience alone (Hartshorne, 2023). AI-powered predictive models provide a transformative approach, leveraging machine learning (ML), deep learning, and natural language processing (NLP) to identify hidden patterns and relationships in large-scale biomedical, clinical, and pharmacological datasets (Banerjee et al., 2022; Ganesh et al., 2022). These models not only accelerate the detection of previously unknown DDIs but also enable proactive intervention strategies to improve patient safety (Ogbuagu et al., 2023; Soldatos et al., 2022).

3.1 Core Applications of AI in DDI Prediction

AI models are increasingly applied in three key areas:

- **Pattern Recognition in Clinical Data:** ML algorithms analyze electronic health records (EHRs), adverse event reports, and prescription histories to uncover novel interaction trends (Soldatos et al., 2022; Shirazibeheshti et al., 2023).
- **Molecular and Pharmacological Modeling:** Deep learning methods integrate molecular docking simulations, protein-ligand interactions, and pathway data to predict potential cross-reactivity between drugs (Mahmood, 2019; Selvaraj et al., 2021).

- **Decision Support and Risk Stratification:** AI-driven clinical decision support tools flag high-risk patients, optimize prescribing decisions, and enable personalized treatment planning (Ganti, 2023; Prakash et al., 2023).

3.2 Frameworks and Techniques in Predictive DDI Modeling

Different AI/ML techniques contribute uniquely to DDI detection, as summarized below.

Table 2. AI Techniques Applied in Predictive Modeling of Drug-Drug Interactions

AI Technique	Application in DDI Prediction	Key References
Machine Learning (SVM, Random Forest, XGBoost)	Classification of drug interaction risks using EHRs, pharmacovigilance reports, and structured clinical data	Banerjee et al., 2022; Mittal et al., 2023
Deep Learning (Neural Networks, Graph Neural Networks)	Modeling nonlinear relationships between drugs, predicting novel interactions from molecular structures	Ganesh et al., 2022; Mahmood, 2019
Natural Language Processing (NLP)	Mining biomedical literature, clinical notes, and adverse event narratives to identify emerging DDIs	Soldatos et al., 2022; Roski et al., 2019
Drug Repurposing AI Models	Detecting potential off-target interactions during repurposing of existing drugs	Selvaraj et al., 2021; Niazi, 2023
Hybrid Models (Molecular + Clinical Data)	Combining molecular docking results with patient-level data for high-confidence DDI predictions	Shirazibeheshti et al., 2023; Gellert et al., 2023



Fig 1: The multi-layered flow diagram for AI-driven DDI prediction, showing data inputs, AI/ML techniques, outputs, and feedback loops for continuous learning.

3.3 Implications for Clinical Practice

AI-powered predictive models hold significant promise for reducing adverse events in polypharmacy patients by enabling early identification of risky drug combinations (Ogbuagu et al., 2023; Hartshorne, 2023). When integrated into clinical decision support systems, these tools can improve clinician confidence, streamline prescribing, and contribute to the personalization of medication regimens (Ganti, 2023; Gellert et al., 2023). While interpretability and regulatory approval remain challenges, advances in explainable AI and FDA guidance (Niazi, 2023) signal a clear path toward clinical adoption.

4. Advances in AI for Drug Discovery and Development

Artificial intelligence (AI) is revolutionizing the pharmaceutical pipeline, from early discovery through development, testing, and clinical deployment. Traditional drug development processes are costly, lengthy, and prone to high failure rates. AI-powered predictive systems accelerate these processes by improving target identification, repurposing opportunities, safety assessments, and pharmacovigilance (Banerjee et al., 2022; Mahmood, 2019). This progress is particularly relevant to polypharmacy patients, where rapid detection of drug-drug interactions (DDIs) can mitigate risks and optimize therapeutic outcomes (Hartshorne, 2023).

4.1 AI in Drug Discovery and Repurposing

AI and machine learning models are increasingly employed for molecular property prediction, binding affinity estimation, and in silico screening. These tools enable rapid identification of promising drug candidates and their potential interactions (Mittal et al., 2023). Beyond discovery, AI-driven drug repurposing has emerged as a key strategy, leveraging existing compounds to uncover new therapeutic uses while simultaneously identifying possible DDI risks (Selvaraj et al., 2021).

4.2 Development and Regulatory Integration

Regulatory agencies, including the FDA, recognize the growing role of AI in drug development and clinical testing. AI/ML approaches support predictive toxicology, dose optimization, and adverse event detection, thereby aligning innovation with safety and compliance (Niazi, 2023). This convergence of AI with regulatory science enhances pharmacovigilance and expedites safe integration into clinical workflows (Soldatos et al., 2022).

4.3 Clinical Application and Personalization

Within clinical settings, AI tools are enabling personalized medicine by tailoring polypharmacy regimens to individual patient risk profiles. Predictive modeling optimizes medication combinations, improves adherence, and minimizes harmful interactions

(Ogbuagu et al., 2023; Ganti, 2023). Importantly, these applications bridge the gap between bench research and bedside care, advancing precision therapeutics (Ganesh et al., 2022; Roski et al., 2019).

Table 3. Applications of AI Across Drug Discovery and Development Phases

Stage	AI Applications	Key Benefits	References
Drug Discovery	Molecular modeling, binding affinity prediction, high-throughput virtual screening	Faster candidate identification, reduced costs	Banerjee et al., 2022; Mahmood, 2019
Drug Repurposing	Knowledge graph mining, deep learning-based similarity analysis	Identification of novel therapeutic uses; improved DDI detection	Selvaraj et al., 2021
Preclinical Development	Predictive toxicology, simulation of pharmacokinetics and pharmacodynamics	Reduced animal testing, early risk detection	Mittal et al., 2023
Clinical Trials	Patient stratification, AI-driven trial design, adverse event prediction	Improved trial efficiency, early identification of risks	Niazi, 2023; Soldatos et al., 2022
Regulatory Science	AI-supported pharmacovigilance, automated analysis of adverse event reports	Stronger compliance, enhanced patient safety monitoring	Soldatos et al., 2022
Clinical Application	Personalized polypharmacy optimization, AI-powered clinical pathway planning	Reduced DDIs, improved adherence, enhanced therapeutic outcomes	Ogbuagu et al., 2023; Ganti, 2023
Post-Marketing Surveillance	Integration of molecular and real-world data for long-term safety monitoring	Continuous DDI detection and refinement of clinical guidelines	Hartshorne, 2023; Ganesh et al., 2022



Fig 2: The stacked bar chart showing how different AI applications (predictive modeling, NLP, deep learning) contribute at each stage of the drug development pipeline. It visually emphasizes the increasing and varied role of AI as the process advances.

5. Challenges and Future Directions

Despite the transformative potential of AI-powered predictive models in detecting novel drug-drug interactions (DDIs) in polypharmacy patients, several challenges remain that must be addressed to ensure safe, transparent, and clinically meaningful adoption.

5.1 Challenges

1. **Data Quality and Integration**
   AI models depend heavily on high-quality datasets drawn from diverse sources such as electronic health records, adverse event reporting systems, and molecular databases. However, issues of incomplete, biased, and fragmented data pose significant risks to the accuracy and generalizability of predictive models (Soldatos et al., 2022; Hartshorne, 2023).
2. **Interpretability and Transparency**
   Many AI algorithms function as "black boxes," making it difficult for clinicians to understand how predictions are derived. Lack of interpretability may reduce trust and hinder integration into prescribing workflows (Roski et al., 2019; Ganesh et al., 2022).
3. **Regulatory and Ethical Concerns**
   Regulatory frameworks for AI in drug safety remain under development. Ethical concerns around patient privacy, algorithmic bias, and liability in case of incorrect predictions create barriers to full-scale adoption (Niazi, 2023; Mahmood, 2019).
4. **Clinical Workflow Integration**
   AI systems must be seamlessly integrated into clinical decision support systems (CDSS) to avoid overwhelming clinicians with alerts or creating workflow inefficiencies (Ogbuagu et al., 2023; Gellert et al., 2023).
5. **Generalizability Across Populations**
   Polypharmacy risk profiles vary across regions and populations. AI models trained on limited datasets may not capture diverse patient populations, raising equity concerns (Shirazibeheshti et al., 2023; Banerjee et al., 2022).

Table 4: Key Challenges and Strategic Directions for AI-Powered DDI Detection

Challenge	Description	Strategic Direction
Data Quality and Integration	Incomplete or biased health records undermine model reliability (Soldatos et al., 2022)	Establish standardized, interoperable data pipelines; improve real-world data collection
Interpretability and Transparency	"Black-box" predictions reduce clinician trust (Roski et al., 2019)	Develop explainable AI (XAI) frameworks for clinical interpretability
Regulatory and Ethical Concerns	Unclear regulatory oversight; ethical risks of bias and liability (Niazi, 2023)	Collaborative guidelines with FDA/EMA; ethical AI principles for fairness and privacy
Clinical Workflow Integration	Risk of alert fatigue and workflow disruption (Ogbuagu et al., 2023)	Embed AI into CDSS with adaptive alert thresholds and clinician-friendly interfaces
Generalizability Across Populations	Limited datasets fail to capture diverse patient needs (Shirazibeheshti et al., 2023)	Expand datasets across demographics and regions; apply federated learning models

5.2 Future Directions

Looking ahead, several opportunities can strengthen the role of AI in polypharmacy safety:

- **Explainable AI for Clinical Trust:** Developing transparent AI models will enhance adoption and trust among prescribers (Ganesh et al., 2022; Roski et al., 2019).
- **Personalized Polypharmacy Management:** AI can support precision prescribing by tailoring regimens to individual genetic, behavioral, and clinical profiles (Ganti, 2023; Selvaraj et al., 2021).
- **Regulatory-Grade AI Models:** Strengthening collaboration with regulatory bodies will ensure compliance with evolving FDA and EMA standards (Niazi, 2023).
- **Integration with Virtual Triage Systems:** Linking AI-powered DDI detection with digital triage and telemedicine platforms may improve clinician experience and patient safety (Gellert et al., 2023).
- **Drug Repurposing and Discovery Synergy:** AI-driven repurposing efforts can not only identify new therapeutic uses but also highlight potential DDIs earlier in the drug development cycle (Banerjee et al., 2022; Mahmood, 2019).

6. Conclusion

The introduction of artificial intelligence in drug safety science is a paradigm shift in polypharmacy management and fast identification of new drug-drug interactions (DDIs). The established pharmacovigilance methods are frequently unable to identify the rare or emergent interactions, whereas AI-based predictive frameworks are offered as dynamic tools capable of generating large-scale information on clinical practice, molecular science, and post-marketing surveillance (Soldatos et al., 2022; Banerjee et al., 2022). With the help of machine learning, natural language processing, and advanced analytics, AI allows identifying patterns of interaction earlier, stratifying patients with high risks, and more reasonable prescribing (Hartshorne, 2023; Shirazibeheshti et al., 2023).

The use of AI-based systems also increases the importance of clinical pharmacy in terms of medication adherence, patient-centered care, and integration of predictive tools in a clinical decision support system (Ogbuagu et al., 2023; Ganti, 2023). These innovations also correspond to the regulatory and translational views, in which AI is swiftly coming to be seen as a key facilitator

of safer drug development, clinical testing, and optimization of the personalized therapy (Niazi, 2023; Ganesh et al., 2022). Also, drug repurposing and discovery solutions aided by AI expand prospects of discovering unexpected interactions in changing therapeutic landscapes (Selvaraj et al., 2021; Mahmood, 2019).

Nevertheless, there are still difficulties associated with standardizing data and the ability of AI models to be interpreted as well as the ethical aspects of the implementation of such systems into practical use (Roski et al., 2019). It will be essential to handle such obstacles by designing open and understandable AI models and effective oversight systems to facilitate its use in clinical practices. In the future, predictive modeling powered by AI can deliver an incredible potential to revolutionize the field of pharmacovigilance, minimize the incidence of adverse drug events, and promote precision medicine in the treatment of polypharmacy (Mittal et al., 2023; Gellert et al., 2023).

Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

References

[1] Adebayo, I A. (2022). ASSESSMENT OF PERFORMANCE OF FERROCENE NANOPARTICLE -HIBISCUS CANNABINUS BIODIESEL ADMIXED FUEL BLENDED WITH HYDROGEN IN DIRECT INJECTION (DI) ENGINE. Transactions of Tianjin University. 55. 10.5281/zenodo.16931428.
[2] Adebayo, I. A., Olagunju, O. J., Nkansah, C., Akomolafe, O., Godson, O., Blessing, O., & Clifford, O. (2019). Water-Energy-Food Nexus in Sub-Saharan Africa: Engineering Solutions for Sustainable Resource Management in Densely Populated Regions of West Africa.
[3] Banerjee, D., Rajput, D., Banerjee, S., & Saharan, V. A. (2022). Artificial intelligence and its applications in drug discovery, formulation development, and healthcare. In *Computer Aided Pharmaceutics and Drug Delivery: An Application Guide for Students and Researchers of Pharmaceutical Sciences* (pp. 309-380). Singapore: Springer Nature Singapore.
[4] Ganesh, G. S., Kolusu, A. S., Prasad, K., Samudrala, P. K., & Nemmani, K. V. (2022). Advancing health care via artificial intelligence: from concept to clinic. *European Journal of Pharmacology*, *934*, 175320.
[5] Ganti, V. K. A. T. (2023). Development of an AI-Powered Clinical Pathway Optimizer for Personalized Healthcare Treatment Planning. *American Data Science Journal for Advanced Computations (ADSJAC) ISSN: 3067-4166*, *1*(1).
[6] Gellert, G. A., Rasławska-Socha, J., Marcjasz, N., Price, T., Heyduk, A., Mlodawska, A., ... & Orzechowski, P. (2023). The role of virtual triage in improving clinician experience and satisfaction: a narrative review. *Telemedicine Reports*, *4*(1), 180-191.
[7] Hartshorne, J. (2023). Polypharmacy, artificial intelligence (AI) and rational medication prescribing-The new frontier. *International Dentistry-African Edition*, *13*(6).
[8] Joshua, O, Ovuchi, B, Nkansah, C, Akomolafe, O, Adebayo, I A, Godson, O, and Clifford, O. (2018). Optimizing Energy Efficiency in Industrial Processes: A Multi-Disciplinary Approach to Reducing Consumption in Manufacturing and Petroleum Operations across West Africa.
[9] Karamchand, G., & Aramide, O. O. (2023). AI Deep Fakes: Technological Foundations, Applications, and Security Risks. *Well Testing Journal*, *32*(2), 165-176.
[10] Karamchand, G., & Aramide, O. O. (2023). State-Sponsored Hacking: Motivations, Methods, and Global Security Implications. *Well Testing Journal*, *32*(2), 177-194.
[11] Mahmood, A. (2019). THE ROLE OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY. *International journal of applied biology and forensic*, *3*(4), 245-273.
[12] Mittal, P., Goyal, R., Kapoor, R., & Gautam, R. K. (2023). Artificial intelligence (AI) and machine learning in the treatment of various diseases. In *Computational Approaches in Drug Discovery, Development and Systems Pharmacology* (pp. 139-158). Academic Press.
[13] Niazi, S. K. (2023). The coming of age of AI/ML in drug discovery, development, clinical testing, and manufacturing: the FDA perspectives. *Drug Design, Development and Therapy*, 2691-2725.
[14] Nkansah, C. (2021). Geomechanical Modeling and Wellbore Stability Analysis for Challenging Formations in the Tano Basin, Ghana.
[15] Nkansah, C. (2022). Evaluation of Sustainable Solutions for Associated Gas Flaring Reduction in Ghana's Offshore Operations. 10.13140/RG.2.2.20853.49122.
[16] Nkansah, C. (2023). Advanced Simulation on Techniques for Predicting Gas Behavior in LNG and NGL Operations. *International Journal of Advance Industrial Engineering*. 11. 10.14741/ijaie/v.11.4.1.
[17] Ogbuagu, O. O., Mbata, A. O., Balogun, O. D., Oladapo, O., Ojo, O. O., & Muonde, M. (2023). Artificial intelligence in clinical pharmacy: Enhancing drug safety, adherence, and patient-centered care. *International Journal of Multidisciplinary Research and Growth Evaluation*, *4*(1), 814-822.
[18] Prakash, V., Singh, A., & Yadav, A. (2023). Faculty Category: Clinical.
[19] Roski, J., Hamilton, B. A., Chapman, W., Heffner, J., Trivedi, R., Del Fiol, G., ... & Pierce, J. (2019). How artificial intelligence is changing health and healthcare. *Artificial intelligence in health care: The hope, the hype, the promise, the peril. Washington DC: National Academy of Medicine*, 58.
[20] Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D. Q. (2021). Application of artificial intelligence in drug repurposing: A mini-review. *Current Chinese Science*, *1*(3), 333-345.
[21] Shirazibeheshti, A., Ettefaghian, A., Khanizadeh, F., Wilson, G., Radwan, T., & Luca, C. (2023). Automated detection of patients at high risk of polypharmacy including anticholinergic and sedative medications. *International Journal of Environmental Research and Public Health*, *20*(12), 6178.

[22] Soldatos, T. G., Kim, S., Schmidt, S., Lesko, L. J., & Jackson, D. B. (2022). Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports. *CPT: Pharmacometrics & Systems Pharmacology*, *11*(5), 540-555.

[23] Sunkara, G. (2022). The Role of AI and Machine Learning in Enhancing SD-WAN Performance. *SAMRIDDHI: A Journal of Physical Sciences, Engineering and Technology*, *14*(04), 1-9.